Samsung Bioepis Reveals Ustekinumab Progress
Company Delivers Phase I Data For SB17 Proposed Biosimilar To Stelara
Executive Summary
Samsung Bioepis has reported positive Phase I data for its SB17 ustekinumab candidate, a proposed biosimilar to Stelara.
You may also be interested in...
Sandoz Fills Pipeline Gap With Samsung Bioepis’ Ustekinumab
Sandoz has filled a gap in its biosimilars pipeline by in-licensing Samsung Bioepis’ SB17 ustekinumab biosimilar to Stelara, for commercialization in multiple global markets.
Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon
A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.
Ustekinumab Rivals Face Exclusion Until 2025
Speaking during the firm’s Q2 results call, J&J management has indicated that it does not expect biosimilar competition to Stelara to hit the market until at least 2025.